메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

라이프

Akeso Announces First Patient Enrolled in the Phase III Trial（AK112-312/HARMONi-GI6）of Ivonescimab for First-Line Treatment of Advanced Metastatic Colorectal Cancer

HONG KONG, July 16, 2025 -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce that the first patient has been successfully enrolled in the registration Phase III clinical trial (AK112-312/HARMONi-GI6) of ivonescimab in first-line treatment for advanced metastatic colorectal cancer (mCRC). This randomized, controlled, multi-center Phase III clinical trial for first-line treatment of mCRC is one of the company's key initiatives to address the significant unmet clinical need worldwide with ivonescimab. Colorectal cancer remains the third mo
- 김갑성 기자
- 2025-07-16 09:47
ArkBio's Ziresovir Included into Pediatric RSV Drug Priority List by WHO

SHANGHAI, July 16, 2025 -- In the newly released "Paediatric drug optimization for respiratory syncytial virus (PADO-RSV) meeting report" by Global Accelerator for Paediatric formulations (GAP-f), the World Health Organization (WHO) host network, ziresovir (10mg) has been included in the PADO-RSV priority list. Ziresovir, developed by Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio"), is the first and only RSV antiviral drug to be included in the list. This is the first time WHO has included an anti-RSV drug developed from China in the paediatric drug optimizati
- 김갑성 기자
- 2025-07-16 09:00
AbbVie's 10th 'Week of Possibilities' Unites Employees Across Asia for Community Impact

- 880 AbbVie employees across 7 markets volunteered over 3,000 hours to support vulnerable groups.- Over 650 individuals benefited from 24 volunteer initiatives, delivered in partnership with 17 community organisations across the region. SINGAPORE, July 16, 2025 -- AbbVie employees in Asia participated in the tenth Week of Possibilities (WOP), the AbbVie Foundation's annual global volunteering programme, held in June and July. This unites our employees around the world with a single purpose to serve our local communities. 880 employees across Singapore
- 황정호 기자
- 2025-07-16 09:00
PHASE Scientific Expands INDICAID® Respiratory Portfolio with Exclusive U.S. Launch of Novel FebriDx® Test

FebriDx® is a first-in-class rapid test that differentiates between bacterial and non-bacterial respiratory infections, offering significant potential to address critical unmet needs in patient care by enabling more informed antibiotic use and aiding in the reduction of antimicrobial resistance. Introduction of FebriDx will enhance PHASE Scientific's INDICAID® portfolio and strengthen its leadership in point-of-care respiratory diagnostics. Partnership underscores PHASE Scientific's proven commercial execution in the U.S. market with its extensive nationwide clinical net
- 김갑성 기자
- 2025-07-16 08:54
디바믹스, AI 및 분자동역학 플랫폼 통해 대사질환 신약 개발 돌파구 마련

[ 메디채널 김갑성 기자 ] 쑤저우, 중국 2025년 7월 15일 -- 인공지능(AI) 기반 신약 개발의 선구자인 디바믹스(Divamics)가 첨단 AI 및 분자동역학(molecular dynamics, MD) 플랫폼을 통해 대사 질환 치료제 발전에 핵심적인 역할을 하고 있다고 밝혔다. 이 강력한 플랫폼은 최근 비만 치료를 위한 새로운 이중 작용체(AMY3R/CTR 수용체 작용제)인 BGM1812 설계를 지원했고, 이는 '의약화학 저널(Journal of Medicinal Chemistry)' 2025년 7월호에 발표됐다. 이러한 성과는 파트너사의 신약 개발 파이프라인을 지속적으로 가속화할 수 있도록 지원해 온 디바믹스의 역량을 입증하는 사례다. 협업적 신약 개발에서 AI 기반 효율성 및 정밀도 디바믹스의 플랫폼은 펩타이드-수용체 간 상호작용을 정밀하게 최적화함으로써, BGM1812의 수용체 결합력을 크게 향상시키는 데 핵심적인 역할을 했다. 전임상 연구에서는 BGM1812가 시험관 내(in vitro) 효능이 50% 향상되었고, 생체 내(in vivo) 실험에서도 유의미한 체중 감소와 대사 지표 개선이라는 뛰어난 치료 효
- 김갑성 기자
- 2025-07-16 00:27
Avio Health Launches AI Platform to Turn Disconnected Health Data into Preventive Intelligence

[ 메디채널 김갑성 기자 ] How Avio Health Is Rewiring Medicine for the Age of AI PALO ALTO, Calif. , July 15, 2025 -- Today, Avio Health announced the launch of its proprietary clinical AI platform, which is designed to unify health data and support the shift toward preventative, personalized care. By integrating lab results, wearable data, genomics, imaging, and patient histories, the platform provides both clinicians and—soon—consumers with a comprehensive, actionable view of health status. In current healthcare systems, medical and wellness data are often stored in isolated silos. La
- 김갑성 기자
- 2025-07-15 21:41
Introducing the VARON VP-8G: A Smarter, Lighter Portable Oxygen Concentrator Built for Life on the Move

NEW YORK, July 15, 2025 -- For those who need reliable oxygen support without compromising mobility, VARON proudly introduces the VP-8G portable oxygen concentrator — its lightest and most advanced portable oxygen concentrator to date. Engineered for active users, the VP-8G combines powerful performance with effortless portability, offering eight adjustable pulse flow settings and delivering consistent oxygen purity of 93% ±3%, all in a sleek, travel-ready design. "This isn't just a smaller oxygen machine — it's the freedom to breathe," said VARON
- 김갑성 기자
- 2025-07-15 20:25
OSR Holdings Appoints Dr. Andreas Niethammer as Chief Medical Officer of Vaximm AG, an OSR Company

BASEL, Switzerland and SEOUL, South Korea, July 15, 2025 -- OSR Holdings, Inc. (NASDAQ: OSRH), a global healthcare company dedicated to advancing healthcare outcomes and improving the quality of life for people and their families, today announced the appointment of Dr Andreas Niethammer, M.D., Ph.D., as Chief Medical Officer of Vaximm AG, an OSR Company developing a platform of orally administered target-specific T-cell activators, including VXM01, a clinical stage anti-VEGFR-2. . Dr. Niethammer is an internationally recognized oncology expert with over two decades of experienc
- 김갑성 기자
- 2025-07-15 19:30
Lung Scan Technology Reveals Hidden Secrets of Airway Disease

Scientists Unveil 4DMedical Imaging Breakthrough that Spots Early Lung Disease Missed by Standard Tests LOS ANGELES, July 15, 2025 -- Researchers at Vanderbilt University, Johns Hopkins University, University of Miami, and The Alfred Hospital studied the lungs of subjects including Veterans using technology developed by 4DMedical called X-ray Velocimetry Lung Ventilation Analysis Software (XV LVAS®). Findings of the major, multi-center study were described in the article, "X-ray velocimetry provides temporally and spatially-resolved biomarkers of lung ventilation in sm
- 김갑성 기자
- 2025-07-15 19:07
AIRS Medical Unveils Major SwiftMR® Update, Enabling Greater Autonomy in MRI Operations

SEOUL, South Korea, July 15, 2025 -- AIRS Medical, pioneers in AI-powered solutions for diagnostic imaging, today announced a major update1 to SwiftMR, the software that reduces MRI scan times by up to 50%2 while enhancing image quality. The latest release introduces new capabilities designed to give providers more flexibility and independence in their MRI operations. Putting imaging teams in command AIRS Medical is giving users more control than ever before. With this update, clinical teams can now be trained to personalize scan settings directly within SwiftMR. This
- 김갑성 기자
- 2025-07-15 18:00

이전

41 42 43 44 45 46 47 48 49 50

많이 본 기사

최근기사

2025-09-04_THU

2025-09-03_WED

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 09월 04일 01시 50분